Real‐world evidence of secukinumab in psoriasis treatment–a meta‐analysis of 43 studies.


Meta-analyses of real-world evidence (RWE) studies provide valuable insights from unselected patient populations in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that selectively neutralizes IL-17A, has shown long lasting effectiveness and safety in moderate to severe plaque psoriasis (PsO). Since its license approval in 2015, many RWE studies have been published. Here, we reviewed all available literature on RWE studies involving secukinumab in patients with moderate to severe PsO to evaluate its effectiveness, drug survival and safety. Materials and methods and databases were searched using pre-specified inclusion criteria from 1/1/2015 to 31/5/2019. Outcomes were measured at 3, 6, and 12 months, and analyzed using a meta-package and R statistical software.

More Articles

Additional Publication Details

  • Augustin M
  • Jullien D
  • Martin A
  • Peralta C
Why choose us

We provide solutions to compare safety and efficacy of a product and aid its approval from regulatory authorities and success in the market

Our Mission

Agility to grow with your needs

Recent Awards